Alphatec Holdings (NASDAQ: ATEC) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitabiliy, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Alphatec Holdings and Myriad Genetics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alphatec Holdings 0 0 0 0 N/A
Myriad Genetics 4 8 1 0 1.77

Myriad Genetics has a consensus target price of $21.83, indicating a potential downside of 8.03%. Given Myriad Genetics’ higher probable upside, analysts plainly believe Myriad Genetics is more favorable than Alphatec Holdings.

Earnings & Valuation

This table compares Alphatec Holdings and Myriad Genetics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Alphatec Holdings N/A N/A N/A ($3.37) -0.50
Myriad Genetics $757.30 million 2.14 $122.60 million $0.45 52.76

Myriad Genetics has higher revenue and earnings than Alphatec Holdings. Alphatec Holdings is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alphatec Holdings has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.

Profitability

This table compares Alphatec Holdings and Myriad Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alphatec Holdings -23.27% N/A -29.46%
Myriad Genetics 4.26% 10.53% 6.64%

Insider & Institutional Ownership

20.8% of Alphatec Holdings shares are owned by institutional investors. 34.9% of Alphatec Holdings shares are owned by insiders. Comparatively, 6.2% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Myriad Genetics beats Alphatec Holdings on 7 of the 10 factors compared between the two stocks.

About Alphatec Holdings

Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.

About Myriad Genetics

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Receive News & Ratings for Alphatec Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.